Company Profile
IN8bio Stock Price, News & Analysis
- Ticker:
- INAB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.97 USD (-1.91%)
Close
Last updated: August 6, 2026
15M USD
Market cap
Why the stock is moving
The latest monitored company update is “IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights.” The corresponding closing-price reaction is not yet available.
Company overview
Gamma-Delta T-Cell Therapies
IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells.
Glioblastoma Program
The company's clinical work in glioblastoma evaluates gamma-delta T cells alongside standard treatment, with survival and disease-control data informing potential regulatory discussions.
T-Cell Engager Platform
INB-619 is a next-generation gamma-delta T-cell engager progressing through IND-enabling studies. The broader engager platform is intended to create off-the-shelf approaches that recruit endogenous immune cells.
Future catalysts
Updated median overall-survival data from the glioblastoma program at ASCO 2026.
Initial animal data for INB-619 and the gamma-delta T-cell engager platform during 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of IN8bio (INAB)?
IN8bio (INAB) most recently closed at 0.97 USD, a -1.91% move versus the previous session.
What is the market cap of IN8bio (INAB)?
IN8bio currently has a market capitalization of 15M USD on BioPharmSignal.
What does IN8bio do?
Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease. The platform seeks to use the innate and adaptive properties of gamma-delta T cells to recognize stressed or malignant cells. Glioblastoma Program The company's clinical work in glioblastoma evaluates gamma-delta T cells alongside...
On which exchange is INAB stock listed?
IN8bio (INAB) is associated with NASDAQ, United States, Biopharma.
What is INB-619?
Initial animal data for INB-619 and the gamma-delta T-cell engager platform during 2026.
Which conditions is IN8bio targeting with INB-619?
IN8bio is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does IN8bio describe recent progress with INB-619?
Initial animal data for INB-619 and the gamma-delta T-cell engager platform during 2026.
What is Gamma-Delta?
Gamma-Delta T-Cell Therapies IN8bio develops gamma-delta T-cell therapies and T-cell engagers for cancer and autoimmune disease.